Compare VRCA & SCOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRCA | SCOR |
|---|---|---|
| Founded | 2013 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.5M | 101.6M |
| IPO Year | 2018 | 2007 |
| Metric | VRCA | SCOR |
|---|---|---|
| Price | $5.54 | $7.18 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $17.00 | N/A |
| AVG Volume (30 Days) | ★ 36.0K | 34.4K |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 127.37 |
| EPS | N/A | ★ N/A |
| Revenue | $35,577,000.00 | ★ $403,549,000.00 |
| Revenue This Year | N/A | $2.75 |
| Revenue Next Year | $94.44 | $7.30 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 370.22 | 1.02 |
| 52 Week Low | $3.28 | $4.81 |
| 52 Week High | $9.82 | $10.18 |
| Indicator | VRCA | SCOR |
|---|---|---|
| Relative Strength Index (RSI) | 40.43 | 53.60 |
| Support Level | $5.32 | $6.97 |
| Resistance Level | $6.60 | $7.81 |
| Average True Range (ATR) | 0.47 | 0.41 |
| MACD | -0.07 | 0.04 |
| Stochastic Oscillator | 22.10 | 71.56 |
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.
comScore Inc is a information and analytics company that measures advertising, content, and the consumer audiences of each, across media platforms. It create products using a data platform that combines information on digital platforms (connected televisions, mobile devices, tablets and computers), televisions, direct to consumer applications, and movie screens with demographics and other descriptive information. The company has developed proprietary data science that enables measurement of person-level and household-level audiences, removing duplicated viewing across devices and over time. Its segments include Content & Ad Measurement and Research & Insight Solutions of which the Content & Ad Measurement segment derives the majority of the revenue.